TARS | Tarsus Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	28.14 - 31.21
52 Week Range	12.57 - 42.50
Beta	0.96
Implied Volatility	80.82%
IV Rank	18.32%
Day's Volume	1,587,587
Average Volume	780,248
Shares Outstanding	38,041,700
Market Cap	1,163,695,603
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-10-16

Valuation
Profitability
Growth
Health
P/E Ratio	-7.30
Forward P/E Ratio	N/A
EPS	-4.19
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	244
Country	USA
Website	TARS

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

TARS's peers: ALDX, CNTA, CRMD, DBVT, ETON, SLN, LIAN, TVTX, CNTB, ABOS, NUVB, ELDN, OPT, NUVL, GNFT, GLUE, DSGN, HOWL, IKNA, STOK, PEPG, TYRA, TRDA, PHVS, RLYB, THTX, VERA

*Chart delayed

Analyzing fundamentals for TARS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see TARS Fundamentals page.

Watching at TARS technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on TARS Technicals page.